ZFHX3 gene mutation used as SCLC immunotherapy biomarker

The invention relates to a biomarker for immunotherapy of SCLC patients, and the biomarker is a mutant ZFHX3 gene. According to the invention, genome and transcriptomics sequencing is carried out on SCLC patient samples (including tumors and paired normal samples), deep analysis finds that the SCLC patient with ZFHX3 gene mutation has high immunity and good prognosis, and clinical test results further prove that the patient with ZFHX3 gene mutation has high pathologic remission rate (MPR), and the SCLC patient with ZFHX3 gene mutation has good clinical application prospects. The SCLC patient with ZFHX3 mutation is prompted to be possibly benefited from immunotherapy, the current situation that the SCLC is lack of immunotherapy biomarkers is filled, and the immunotherapy biomarkers have important significance on the immunotherapy of the SCLC patient. 本发明涉及一种与SCLC患者免疫治疗的生物标志物，为突变型ZFHX3基因。本发明通过对SCLC患者样本(包含肿瘤和配对的正常样本)进行基因组和转录组学的测序，深入分析发现ZFHX3基因突变的SCLC患者存在较高的免疫，预后较好，临床试验的结果进一步证实ZFHX3基因突变的患者病理缓解率(MPR)更高，提示存在ZFHX3突变